biotech / news / / Washington Examiner
The rhetoric marshalled by the conservative groups to oppose President Donald Trump’s drug pricing policy aligns with that used by PhRMA itself.
PhRMA-funded conservative groups' rhetoric opposing Trump’s drug pricing plan exactly matches PhRMA’s messaging.
KEY POINTS
- Several PhRMA-funded groups received over $1 million between 2019 and 2024 from the trade association.
- Some coverage of these groups' opposition to Trump’s policy omitted their pharmaceutical industry funding.
- PhRMA blames pharmacy benefit managers and 340B abuses for high drug prices, arguments echoed by its funded groups.
- Industry funding enables PhRMA's positions to gain significant traction in national policy discussions.
COMPANIES
Summarized by Newsio from Washington Examiner. How we summarize →